Tom 16, Nr 3 (2019)
Farmakoterapia chorób układu krążenia
Opublikowany online: 2019-09-24
Wyświetlenia strony
764
Wyświetlenia/pobrania artykułu
2023
Dlaczego warto stosować walsartan i jego skojarzenia u pacjentów z nadciśnieniem tętniczym?
Choroby Serca i Naczyń 2019;16(3):172-183.
Streszczenie
W najnowszych wytycznych dotyczących leczenia nadciśnienia tętniczego określono docelowe wartości ciśnienia na poniżej 130/80 mm Hg u większości pacjentów z zaleceniem, aby terapia hipotensyjna rozpoczynała się od preparatu złożonego (SPC) dwuskładnikowego. Oprócz silnego działania hipotensyjnego stosowanie walsartanu wiąże się z obniżeniem ryzyka metabolicznego oraz zmniejszeniem częstości występowania powikłań narządowych i zdarzeń sercowo-naczyniowych. Walsartan jest jedynym sartanem preferowanym zarówno u pacjentów z nadciśnieniem tętniczym i współistniejącą chorobą wieńcową, jak i u chorych z niewydolnością serca. Zastosowanie skojarzenia walsartanu z amlodipiną lub hydrochlorotiazydem wiąże się z jednej strony z udowodnionym, silniejszym efektem hipotensyjnym, wynikającym z synergistycznego działania obu molekuł, a z drugiej strony z ograniczeniem częstości działań niepożądanych (takich jak obrzęki obwodowe w przypadku monoterapii amlodipiną czy hipokaliemia w przypadku monoterapii hydrochlorotiazydem).
Słowa kluczowe: amlodipinachoroby układu sercowo-naczyniowegohydrochlorotiazydnadciśnienie tętniczeterapia złożonawalsartan
Referencje
- World Health Organization. www.who.int/topics/cardiovascular_diseases/en/ (2.09.2019).
- Tykarski A, Filipiak KJ, Januszewicz A, et al. Zasady postępowania w nadciśnieniu tętniczym — 2019 rok. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1–86.
- Williams B, Mancia G, Spiering W, et al. Authors/Task Force Members:, ESC Scientific Document Group. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104.
- Zdrojewski Ł, Zdrojewski T, Rutkowski M, et al. Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey. Kardiol Pol. 2013; 71(4): 381–392.
- Niklas A, Flotyńska A, Puch-Walczak A, et al. WOBASZ II investigators. Prevalence, awareness, treatment and control of hypertension in the adult Polish population — multi-center National Population Health Examination Surveys — WOBASZ studies. Arch Med Sci. 2018; 14(5): 951–961.
- Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013; 185(11): 949–957.
- Tymińska A, Kapłon-Cieślicka A. Wiek naczyń — u kogo i jak go oceniać? Czy możemy „odmłodzić” naczynia naszych pacjentów? Choroby Serca i Naczyń. 2019; 16(2): 118–129.
- Piepoli MF, Hoes AW, Agewall S, et al. Authors/Task Force Members, Additional Contributor: Simone Binno (Italy), Document Reviewers, ESC Scientific Document Group. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315–2381.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71(6): e13–e115.
- Wright JT, Williamson JD, Whelton PK, et al. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373(22): 2103–2116.
- Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens. 2005; 18(2 Pt 1): 287–294.
- Fogari R, De Gasparo M. Addressing those two that go together: the angiotensin II receptors and their role in blood-flow regulation. Blood Press. 2001; 10(1): 6–15.
- Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997; 54(2): 299–311.
- Opolski G, Filipiak KJ. Leki hamujące układ renina–angiotensyna–aldosteron. Urban & Partner, Wrocław 2000.
- Neutel JM. Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker--telmisartan. Blood Press Suppl. 2001; 1: 27–32.
- Gleiter CH, Jägle C, Gresser U, et al. Candesartan. Cardiovasc Drug Rev. 2004; 22(4): 263–284.
- Lacourcière Y, Krzesinski JM, White WB, et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit. 2004; 9(4): 203–210.
- White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens. 2004; 17(4): 347–353.
- Ponikowski P, Voors AA, Anker SD SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
- Pool JL, Glazer R, Chiang YT, et al. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens. 1999; 13(4): 275–281.
- Hermida RC, Calvo C, Ayala DE, et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension. 2003; 42(3): 283–290.
- Hermida RC, Calvo C, Ayala DE, et al. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens. 2005; 23(10): 1913–1922.
- Thürmann PA, Thürmann PA. Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy. J Cardiovasc Pharmacol. 1999; 33(Suppl 1): S33–S36; discussion S41–S43.
- Thürmann PA. Regression of left ventricular hypertrophy following angiotensin II receptor blockade: valsartan on left ventricular hypertrophy. Cardiovasc Rev Rep. 2000; 21: 70–73.
- Kjeldsen SE, Julius S, Mancia G, et al. VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006; 24(7): 1405–1412.
- Pfeffer MA, McMurray J, Velazquez EJ. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349(20): 1893–1906.
- Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345(23): 1667–1675.
- Maggioni AP, Latini R, Carson PE, et al. Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005; 149(3): 548–557.
- Baruch L, Glazer RD, Aknay N, et al. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2004; 148(6): 951–957.
- Majani G, Giardini A, Opasich C, et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. J Card Fail. 2005; 11(4): 253–259.
- Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002; 106(6): 672–678.
- McMurray JJ, Holman RR, Haffner SM, et al. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362(16): 1477–1490.
- Mochizuki S, Dahlöf B, Shimizu M, et al. Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007; 369(9571): 1431–1439.
- Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118): 1755–1762.
- Bakris GL. Maximizing cardiorenal benefit in the management of hypertension: achieve blood pressure goals. J Clin Hypertens (Greenwich). 1999; 1(2): 141–147.
- Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin. 2008; 24(8): 2389–2401.
- Calhoun DA. Use of single-pill combination therapy in the evolving paradigm of hypertension management. Expert Opin Pharmacother. 2009; 10(12): 1869–1874.
- Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007; 29(4): 563–580.
- Barylski M. Dwanaście powodów, dla których warto stosować amlodipinę. Med Fakt. 2014; 7: 41–47.
- Kurtz A. Do calcium-activated chloride channels control renin secretion? News Physiol Sci. 1990; 5(2): 43–46.
- Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs. 1995; 50(3): 560–586.
- Takayama M, Arakawa E, Yao K, et al. Effects of combination of angiotensin receptor blocker and calcium channel blocker on ox-LDL levels and cardiovascular dysfunction in Dahl rats. Pharmacology. 2006; 77(4): 179–187.
- Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007; 21(3): 220–224.
- Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs. 2007; 67(9): 1309–1327.
- Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens. 2011; 29(7): 1270–1280.
- Trenkwalder P, Schaetzl R, Borbas E, et al. Efficacy and safety of the combination of amlodipine 10/valsartan 160 in hypertensive patients not controlled by the combination of ramipril 5/felodipine 5. The EXPRESS-C trial. J Hypertens. 2007; 25(Suppl 2): S228 (abstract P24.261).
- Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich). 2008; 10(3): 185–194.
- Karpov Y, Dongre N, Vigdorchik A, et al. Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension. Adv Ther. 2012; 29(2): 134–147.
- Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009; 23(7): 479–489.
- Kaplan NM. The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide. Hypertension. 2009; 54(5): 951–953.
- van Brummelen P, Man in 't Veld AJ, Schalekamp MA. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther. 1980; 27(3): 328–336.
- Weir MR, Levy D, Crikelair N, et al. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens. 2007; 20(7): 807–815.
- Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007; 29(1): 61–73.
- Nash DT, McNamara MS. Valsartan combination therapy in the management of hypertension — patient perspectives and clinical utility. Integr Blood Press Control. 2009; 2: 39–54.
- Calhoun DA, Glazer RD, Pettyjohn FS, et al. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin. 2008; 24(8): 2303–2311.
- Lacourciere Y, Hebert D, Assouline L, et al. Effective blood-pressure control with valsartan/HCTZ combination therapy in patients with moderate to severe systolic hypertension: the VALOR trial. Am J Hypertens. 2004; 17(5): S115 (abstract P-225).
- White WB, Calhoun DA, Samuel R, et al. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich). 2008; 10(6): 450–458.
